CBD

Abstract Background: Three-dimensional printing (3DP) is rapidly advancing personalised medicine, yet systematic performance comparison with conventional manufacturing remains limited, particularly...

Abstract Cannabidiol (CBD) exhibits poor oral bioavailability (approximately 6%) due to low solubility and excessive first-pass metabolism, limiting its therapeutic...

Abstract Cannabidiol (CBD) is a non-psychoactive compound derived from Cannabis sativa. It has attracted significant attention for its anti-inflammatory, pain-relieving, and...

Abstract Background/Objectives: Cannabidiol (CBD) has emerged as a potential therapeutic agent for respiratory disorders, including asthma and chronic obstructive pulmonary...

Formulation technologies provide a powerful tool in product innovation and new applications especially for purified and highly concentrated extracts including...

Abstract Mesoporous silica-based liquisolids offer an effective method for transforming liquid or sticky actives, such as cannabis extracts, into free-flowing...

Abstract Background/Objectives: Cannabinoids are increasingly recognised for their therapeutic potential beyond well-established indications such as chronic pain, multiple sclerosis, and specific...

Abstract Background: Phytocannabinoids such as cannabidiol (CBD) and cannabigerol (CBG) have received increasing attention in the context of inflammatory and...

Abstract Pulmonary delivery can deliver cannabidiol (CBD) with high bioavailability and fast onset of action. One formulation obstacle is the...

The legal status of THC (Tetrahydrocannabinol) in Europe varies widely. This patchwork creates challenges for consumers, producers, and businesses in the cannabis...